Stocks · News reference
BTIG analyst Mark Massaro maintains Adaptive Biotechnologies (NASDAQ:ADPT) with a Buy and raises the price target from $25 to $34.
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Updated guidelines establish a dedicated framework for routine MRD assessment across the multiple myeloma patient journeyclonoSEQ named as an FDA-cleared assay for MRD assessment, with 10-6 sensitivity now
U.S. futures were mixed; ServiceTitan plunged 16.7% on weak Q3 guidance, while Mind Technology, Braze and others also fell premarket.
Piper Sandler analyst David Westenberg maintains Adaptive Biotechnologies (NASDAQ:ADPT) with a Overweight and raises the price target from $20 to $27.5.